Publication:
Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy

0
0

Issued Date

2013

Resource Type

Article

File Type

application/pdf

ISSN

9042512

DOI

10.1111/jop.12023

Other identifier(s)

2-s2.0-84874719122

Rights Holder(s)

Scopus

Bibliographic Citation

Journal of Oral Pathology and Medicine. Vol 42, No.3 (2013), p.208-215

Suggested Citation

Nittayananta W., Kemapunmanus M., Yangngam S., Talungchit S., Sriplung H. Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy. Journal of Oral Pathology and Medicine. Vol 42, No.3 (2013), p.208-215. doi:10.1111/jop.12023 Retrieved from: https://hdl.handle.net/20.500.14740/6706

Title

Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy

Author(s)

Nittayananta W.
 Kemapunmanus M.
 Yangngam S.
 Talungchit S.
 Sriplung H.

Abstract

Background: The objectives of this study were to determine (i) the expression of oral secretory leukocyte protease inhibitor (SLPI) in HIV-infected subjects compared with non-HIV controls, (ii) the oral SLPI expression in HIV-infected subjects with antiretroviral therapy (ART) compared with those without ART, and (iii) factors associated with the expression of oral SLPI. Methods: Oral tissues and samples of both un-stimulated and stimulated saliva were collected from HIV-infected subjects with and without ART, and non-HIV individuals. The expression of SLPI mRNA in the tissue was determined by quantitative real-time PCR. Salivary SLPI protein was detected using ELISA. Chi-square test and logistic regression analysis were performed to determine the association between HIV/ART status and the expression of oral SLPI. Results: One hundred and fifty-seven HIV-infected subjects were enrolled: 99 on ART (age range, 23-57 years; mean, 39 years), 58 not on ART (age range, 20-59 years; mean, 34 years), and 50 non-HIV controls (age range, 19-59 years; mean, 36 years). The most common ART regimen was 2NRTIs + 1NNRTI. The expression of oral SLPI in stimulated saliva was significantly decreased with HIV infection (P < 0.001). The expression was also significantly different with respect to ART use (P = 0.007). Smoking, CD4+ cell count, and HIV viral load were the factors associated with the oral SLPI expression. Conclusion: The expression of oral SLPI is altered by HIV infection and use of ART. Thus, oral SLPI may be the useful biomarker to identify subjects at risk of infections and malignant transformation due to HIV infection and long-term ART.© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Subject(s)

Antiretrovirus agent
 Messenger RNA
 Nonnucleoside reverse transcriptase inhibitor
 Proteinase inhibitor
 RNA directed DNA polymerase inhibitor
 Secretory leukocyte proteinase inhibitor
 Adult
 Article
 CD4 lymphocyte count
 Controlled study
 Enzyme linked immunosorbent assay
 Human
 Human immunodeficiency virus
 Human immunodeficiency virus infection
 Innate immunity
 Major clinical study
 Mouth
 Priority journal
 Protein expression
 Real time polymerase chain reaction
 Virus load
 Adult
 Alcohol Drinking
 Anti-HIV Agents
 Anti-Retroviral Agents
 Biological Markers
 CD4 Lymphocyte Count
 Cross-Sectional Studies
 Female
 Gingival Hemorrhage
 HIV
 HIV Infections
 Humans
 Male
 Middle Aged
 Mouth Mucosa
 Oral Health
 Periodontal Pocket
 Saliva
 Salivary Proteins and Peptides
 Secretory Leukocyte Peptidase Inhibitor
 Secretory Rate
 Serine Proteinase Inhibitors
 Smoking
 Time Factors
 Viral Load
 Young Adult
 Zidovudine

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/6706

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By